Here are the DEF 14A proxy statements from Quantum Cyber N.V. (QUCY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow QUCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QUCY filings page.
Quantum Cyber N.V. is asking shareholders to approve 11 proposals at its June 29, 2026 annual meeting in Amsterdam, with a record date of June 1, 2026. Items include ratifying Kreston Lentink as Dutch auditor for 2026, adopting Dutch statutory annual accounts for 2025 and granting directors discharge from liability for 2025 activities.
The Board also seeks to extend its authority to issue all unissued share capital and to limit or exclude pre-emption rights until June 28, 2031. Additional proposals would extend authorizations for repurchases of ordinary and preferred shares, approve past and future Board resolutions connected to new strategic initiatives, amend the articles to expand the corporate objects into quantum computing, next-generation cybersecurity and autonomous defense platforms, appoint Peter O’Rourke as director, and substantially amend the directors’ remuneration policy.
Mainz Biomed N.V. has called an extraordinary shareholders’ meeting on April 22, 2026 to vote on a transformative financing and capital structure package, board changes and governance items. Shareholders are being asked to ratify Reliant CPA as auditor and approve issuances of ordinary shares underlying five series of preferred shares issued or to be issued to investor David E. Lazar to comply with Nasdaq Listing Rules 5635(b) and 5635(d). The preferred shares, once fully convertible, would represent in excess of 95% of issued and outstanding ordinary shares on a fully diluted basis after a planned second $3 million closing.
Further proposals would authorize specific conversion ratios for all five preferred series, increase authorized capital to up to 900,000,000 ordinary shares and 100,000,000 preferred shares on a post–reverse split basis, change the company’s name to Quantum Cyber N.V., and approve a reverse share split in a range of 1‑for‑2 to 1‑for‑100 to help regain Nasdaq’s $1.00 minimum bid price after a deficiency notice. Shareholders will also vote on appointing four directors (including Lazar as CEO), expanding the 2025 Omnibus Incentive Plan to 10,000,000 ordinary shares, updating the remuneration policy and formally approving board resolutions related to the Lazar purchase agreement. The company warns that failure to obtain approvals could block the final closing, leave restrictive covenants in place, constrain new financing and potentially force a sale of assets or receivership.